Literature DB >> 10492635

Prospective evaluation of the International Neuroblastoma Staging System (INSS) and the International Neuroblastoma Response Criteria (INRC) in a multicentre setting.

V Castel1, P García-Miguel, A Cañete, C Melero, A Navajas, J I Ruíz-Jiménez, S Navarro, M D Badal.   

Abstract

The aim of this study was to classify prospectively a series of neuroblastoma tumours according to the International Neuroblastoma Staging System (INSS) and the International Neuroblastoma Response Criteria (INRC) and to evaluate the difficulties and pitfalls involved in a multicentre setting. Each hospital provided their data for central review. The surgical procedures and their complications were reported. Kaplan-Meier estimates of survival and event-free survival were calculated according to stage and response to therapy. From June 1992 to December 1996, 194 patients were included in the study, with a mean age of 2 years. Initial studies were performed according to INSS recommendations without major problems. INSS stage was correctly applied to all patients except for 9 (95%). Post-operative complications were observed in 15 patients (8.3%). Response to therapy (INRC) was studied in 63 stage 4 patients, 11 of whom were not classified correctly (17%). Differences in survival according to stage (INSS) and group of response to therapy (INRC) were statistically significant (P < 0.001). In conclusion the INSS was easy to use and separated different prognostic groups. Surgical complications and mortality did not increase in this series because of using the INSS. The feasibility of INRC was evaluated in a small series of stage 4 patients and the designation of response was problematic in a relatively high proportion of cases. The prognostic value of the different responses was highly significant, but less informative than had been hoped for.

Entities:  

Mesh:

Year:  1999        PMID: 10492635     DOI: 10.1016/s0959-8049(98)00395-5

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  11 in total

1.  Association between end-induction response according to the revised International Neuroblastoma Response Criteria (INRC) and outcome in high-risk neuroblastoma patients.

Authors:  Erin K Barr; Kathryn Laurie; Kristen Wroblewski; Mark A Applebaum; Susan L Cohn
Journal:  Pediatr Blood Cancer       Date:  2020-07-25       Impact factor: 3.167

Review 2.  [Neuroblastoma].

Authors:  Victoria Castel; Adela Cañete; Rosa Noguera; Samuel Navarro; Silvestre Oltra
Journal:  Clin Transl Oncol       Date:  2005-04       Impact factor: 3.405

3.  [Clinical features of neuroblastoma: an analysis of 44 children].

Authors:  Cheng-Guang Zhu; Xiang-Ling He; Zhi-Ge Tang; Ke-Ke Chen; Run-Ying Zou; Xin Tian; Ya-Lan You
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2020-11

4.  Fetal neuroblastoma: ultrasonography and magnetic resonance imaging findings in the prenatal and postnatal IV-S stage.

Authors:  Heron Werner; Pedro Daltro; Taisa Davaus; Edward Araujo Júnior
Journal:  Obstet Gynecol Sci       Date:  2016-09-13

5.  Knockdown of astrocyte elevated gene-1 inhibits proliferation and enhancing chemo-sensitivity to cisplatin or doxorubicin in neuroblastoma cells.

Authors:  Haiyan Liu; Xianrang Song; Chunxi Liu; Li Xie; Ling Wei; Ruopeng Sun
Journal:  J Exp Clin Cancer Res       Date:  2009-02-15

Review 6.  Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trials.

Authors:  Wendy B London; Rochelle Bagatell; Brenda J Weigel; Elizabeth Fox; Dongjing Guo; Collin Van Ryn; Arlene Naranjo; Julie R Park
Journal:  Cancer       Date:  2017-09-08       Impact factor: 6.860

7.  Implications of Image-Defined Risk Factors and Primary-Site Response on Local Control and Radiation Treatment Delivery in the Management of High-Risk Neuroblastoma: Is There a Role for De-escalation of Adjuvant Primary-Site Radiation Therapy?

Authors:  John T Lucas; M Beth McCarville; David A Cooper; Mikhail Doubrovin; Daniel Wakefield; Teresa Santiago; Yimei Li; Xingyu Li; Matthew Krasin; Victor Santana; Wayne Furman; Andrew M Davidoff
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-11-26       Impact factor: 7.038

8.  Downregulation of survivin by siRNA inhibits invasion and promotes apoptosis in neuroblastoma SH-SY5Y cells.

Authors:  L Zhang; H Liang; W Cao; R Xu; X L Ju
Journal:  Braz J Med Biol Res       Date:  2014-05-23       Impact factor: 2.590

9.  Clinical Features of Neuroblastoma With 11q Deletion: An Increase in Relapse Probabilities In Localized And 4S Stages.

Authors:  Antonio Juan Ribelles; Sandra Barberá; Yania Yáñez; Pablo Gargallo; Vanessa Segura; Bárbara Juan; Rosa Noguera; Marta Piqueras; Victoria Fornés-Ferrer; Jaime Font de Mora; Adela Cañete; Victoria Castel
Journal:  Sci Rep       Date:  2019-09-24       Impact factor: 4.379

10.  High-dose chemotherapy and autologous stem cell rescue in patients with high-risk stage 3 neuroblastoma: 10-year experience at a single center.

Authors:  Jung Min Suh; Keon Hee Yoo; Ki Woong Sung; Ju Youn Kim; Eun Joo Cho; Hong Hoe Koo; Suk Koo Lee; Jhingook Kim; Do Hoon Lim; Yeon Lim Suh; Dae Won Kim
Journal:  J Korean Med Sci       Date:  2009-07-29       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.